Oaktree Acquisition Corp. III Life Sciences — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Oaktree Acquisition Corp. III Life Sciences shareholders approved a special resolution on October 23, 2026, extending the business combination deadline from November 25, 2026 to May 25, 2027 (six one-month extensions possible by board resolution). The amended Article 164(a) specifies that if no business combination closes by the extended deadline, the company will redeem all public shares at trust fund value (less up to $100,000 in wind-down costs) and liquidate. Public shareholders retain redemption rights if the extension terms are further modified.
Why this rating
Extension is routine SPAC governance for a $200M-cap blank-check company; neither value-accretive nor destroying. Maintains shareholder protections but signals deal completion challenges.
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.